U.S. markets closed

NeuroPace, Inc. (NPCE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
24.86+0.06 (+0.24%)
At close: 4:00PM EDT
25.09 +0.23 (0.93%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close24.80
Open24.99
Bid24.94 x 800
Ask25.14 x 1100
Day's Range24.09 - 25.37
52 Week Range18.24 - 27.38
Volume94,306
Avg. Volume247,886
Market Cap603.877M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateJun 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • NeuroPace Reports First Quarter 2021 Financial Results and Provides 2021 Financial Guidance
    GlobeNewswire

    NeuroPace Reports First Quarter 2021 Financial Results and Provides 2021 Financial Guidance

    MOUNTAIN VIEW, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ended March 31, 2021. Recent Highlights Total revenue of $11.2 million for the first quarter of 2021, representing a 12% increase over the comparable prior year period in 2020Initial implant revenue of $8.1 million for the first quarter of 2021, repre

  • ACCESSWIRE

    NeuroPace Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / June 3, 2021 / NeuroPace Inc (NASDAQ:NPCE) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on June 3, 2021 at 8:00 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.

  • NeuroPace To Report First Quarter 2021 Financial Results on June 3, 2021
    GlobeNewswire

    NeuroPace To Report First Quarter 2021 Financial Results on June 3, 2021

    MOUNTAIN VIEW, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the first quarter of 2021 before market open on Thursday, June 3, 2021. The company’s management will webcast a corresponding conference call beginning at 5:00 a.m. Pacific Time /8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844) 955-2173 for domestic callers or (914) 987-7949 for international callers, using conference ID: 1485513. Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://investors.neuropace.com. The webcast will be archived and available for replay for at least 90 days after the event. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. Investor Contact:Gilmartin GroupMatt Bacso, CFAinvestors@neuropace.com